Matches in SemOpenAlex for { <https://semopenalex.org/work/W133118047> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W133118047 endingPage "94" @default.
- W133118047 startingPage "1089" @default.
- W133118047 abstract "Ninety postmenopausal women with advanced breast cancer were randomly assigned to be treated with HD-MPA administered either by oral route (daily dose 900 mg) or by intramuscular injections (1 g IM daily X 5 q w during 4 consecutive weeks followed by maintenance with 1 g twice weekly). Among 78 evaluable cases, most heavily pretreated, remissions, lasting for a median duration of 11 months, were more frequent on oral (8/37 = 22%) than on IM therapy (5/41 = 12%). In both arms, high estrogen receptor levels and various clinical factors were associated with higher response rates i.e., age greater than 60, Karnofsky greater than 70, light prior systemic treatment. Side-effects, consisting mainly of weight gain, hypertension and tremor occurred with equal frequency on oral or IM treatment. Five patients complained of pain at the sites of IM injections. Thus, we recommended that, whenever possible, the oral route should be preferred. During the same study, in 20 patients (11 on oral and 9 on IM therapy), blood was drawn at 0, 30, and 60 days of treatment for the assessment of MPA and hormone levels. In both arms, at 60 days, comparable levels of circulating MPA were obtained, with a very significant drop of cortisol, androstenedione, and estrone. These endocrine results, together with our clinical data, indicate that HD-MPA therapy is active on estrogen-dependent tumors with the same specificity as that of other modalities aiming to suppress the adrenal function. Its antineoplastic action in humans could be ascribed at least in part to its suppressive action on the adrenals, resulting in a severe estrogenic deprivation in postmenopausal women." @default.
- W133118047 created "2016-06-24" @default.
- W133118047 creator A5001188276 @default.
- W133118047 creator A5008752155 @default.
- W133118047 creator A5019631884 @default.
- W133118047 creator A5030207164 @default.
- W133118047 creator A5048752670 @default.
- W133118047 creator A5058912347 @default.
- W133118047 creator A5073156962 @default.
- W133118047 creator A5073806640 @default.
- W133118047 creator A5079463175 @default.
- W133118047 creator A5084202823 @default.
- W133118047 date "1986-09-01" @default.
- W133118047 modified "2023-10-14" @default.
- W133118047 title "Oral versus intramuscular high-dose medroxyprogesterone acetate (HD-MPA) in advanced breast cancer. A randomized study of the Belgian Society of Medical Oncology." @default.
- W133118047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2948441" @default.
- W133118047 hasPublicationYear "1986" @default.
- W133118047 type Work @default.
- W133118047 sameAs 133118047 @default.
- W133118047 citedByCount "5" @default.
- W133118047 crossrefType "journal-article" @default.
- W133118047 hasAuthorship W133118047A5001188276 @default.
- W133118047 hasAuthorship W133118047A5008752155 @default.
- W133118047 hasAuthorship W133118047A5019631884 @default.
- W133118047 hasAuthorship W133118047A5030207164 @default.
- W133118047 hasAuthorship W133118047A5048752670 @default.
- W133118047 hasAuthorship W133118047A5058912347 @default.
- W133118047 hasAuthorship W133118047A5073156962 @default.
- W133118047 hasAuthorship W133118047A5073806640 @default.
- W133118047 hasAuthorship W133118047A5079463175 @default.
- W133118047 hasAuthorship W133118047A5084202823 @default.
- W133118047 hasConcept C121608353 @default.
- W133118047 hasConcept C126322002 @default.
- W133118047 hasConcept C2775930923 @default.
- W133118047 hasConcept C2775934596 @default.
- W133118047 hasConcept C2776306185 @default.
- W133118047 hasConcept C2777164284 @default.
- W133118047 hasConcept C2778656385 @default.
- W133118047 hasConcept C2780275930 @default.
- W133118047 hasConcept C530470458 @default.
- W133118047 hasConcept C71924100 @default.
- W133118047 hasConceptScore W133118047C121608353 @default.
- W133118047 hasConceptScore W133118047C126322002 @default.
- W133118047 hasConceptScore W133118047C2775930923 @default.
- W133118047 hasConceptScore W133118047C2775934596 @default.
- W133118047 hasConceptScore W133118047C2776306185 @default.
- W133118047 hasConceptScore W133118047C2777164284 @default.
- W133118047 hasConceptScore W133118047C2778656385 @default.
- W133118047 hasConceptScore W133118047C2780275930 @default.
- W133118047 hasConceptScore W133118047C530470458 @default.
- W133118047 hasConceptScore W133118047C71924100 @default.
- W133118047 hasIssue "5" @default.
- W133118047 hasLocation W1331180471 @default.
- W133118047 hasOpenAccess W133118047 @default.
- W133118047 hasPrimaryLocation W1331180471 @default.
- W133118047 hasRelatedWork W133118047 @default.
- W133118047 hasRelatedWork W1971193337 @default.
- W133118047 hasRelatedWork W2028854438 @default.
- W133118047 hasRelatedWork W2102930722 @default.
- W133118047 hasRelatedWork W2121294711 @default.
- W133118047 hasRelatedWork W2275054999 @default.
- W133118047 hasRelatedWork W2414932259 @default.
- W133118047 hasRelatedWork W2466668571 @default.
- W133118047 hasRelatedWork W2804887043 @default.
- W133118047 hasRelatedWork W46523464 @default.
- W133118047 hasVolume "6" @default.
- W133118047 isParatext "false" @default.
- W133118047 isRetracted "false" @default.
- W133118047 magId "133118047" @default.
- W133118047 workType "article" @default.